At the hepatic level, TSS and AE worked in concert to attenuate steatosis by downregulating lipogenic genes, such as SREBP-1c and FAS, while upregulating genes involved in lipolysis and β-oxidation, promoting enhanced fatty acid catabolism. The gene discussed is SREBF1; the disease is steatosis.